nct_id,id,outcome_type,title,description,time_frame,population,units,dispersion_type,param_type
NCT04646109,6045646,Secondary,Treatment-Related Adverse Events as Assessed by CTCAE v4.0,"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted.",From the 6th day of study to the 10th day of study,,Participants,,Count of Participants
NCT04646109,6045647,Secondary,Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity,"At the end of the follow-up period (10th day), patients in the study and control group were investigated by PCR test for SARS-CoV-2 and the negative results were recorded as percentage for both groups.",At the end of 10th day,PCR test was applied to 8 patients in the control group and 16 patients in the study group at the end of the study (secondary endpoint).,Participants,,Count of Participants
NCT04646109,6045648,Secondary,Changes in Serum D-dimer Levels,"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum D-dimer levels (mg/L) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in Serum D-dimer levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum D-dimer level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,mg/L,Standard Deviation,Mean
NCT04646109,6045649,Secondary,Changes in Serum Ferritin Levels,"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum ferritin levels (mg/dL) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum ferritin levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum ferritin level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,mg/dL,Standard Deviation,Mean
NCT04646109,6045650,Secondary,Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L),"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PNL/L ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PNL/L ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PNL/L ratio at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,Ratio,Standard Deviation,Mean
NCT04646109,6045651,Secondary,Changes in Serum Lymphocyte Counts,"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum lymphocyte counts (cell/mm^3) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum lymphocyte counts on the 6th, 8th and 10th days was calculated graphically, the change in the serum lymphocyte count at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,cell/mm^3,Standard Deviation,Mean
NCT04646109,6045652,Secondary,Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2),"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PaO2/FiO2 ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PaO2/FiO2 ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 10th day (secondary endpoint) with the baseline ratio was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,Ratio,Standard Deviation,Mean
NCT04646109,6045653,Secondary,Changes in Oxygen Saturation (SpO2) Values,"In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). SpO2 values at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in SpO2 values on the 6th, 8th and 10th days was calculated graphically, the change in the SpO2 value at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value).",From 6th to the end of 10th day,,percentage of peripheral capillary O2,Standard Deviation,Mean
NCT04646109,6045654,Secondary,Mortality,The number of died patients were evaluated in study and control groups,"Through study completion, an average of 3 months",,Participants,,Count of Participants
NCT04646109,6045655,Secondary,Number of Participants With Clinical Response,"The presence of at least two of the following criteria in patients on the 10th day were accepted as clinical response: Respiration rate between 22-24/min, SpO2 level in room air >95%, absence of oxygen requirement, observation of radiological improvement in control lung tomography and no need for intensive care.",10 days (5 days ivermectin therapy plus 5 days follow-up),,Participants,,Count of Participants
NCT04646109,6045667,Primary,Heart Rate Means of the Patients,"At the beginning of the study, the heart rates (as per minute) of the patients were measured and the mean heart rate values of both groups were recorded.",At the first day of the study,,beats per minute,Standard Deviation,Mean
NCT04646109,6045656,Primary,Treatment-Related Adverse Events as Assessed by CTCAE v4.0,"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted.",At the first 5 days of study,,Participants,,Count of Participants
NCT04646109,6045657,Primary,Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism,"A blood sample was taken from the patients included in the study group, after taking or during the first dose of ivermectin. From the blood samples, haplotypes and mutations that cause the function losing were investigated by performing sequence analysis of multidrug resistance 1 (MDR1)/ABCB1 and CYP3A4 genes with Sanger method. In case of detection of mutation, the patient were excluded from the study and if observed, side effects of ivermectin were noted.",At the first day of ivermectin therapy (1st day),"We aimed to investigate the effectiveness/safety of adding ivermectin to the COVID-19 treatment in patients without mutation. Since ivermectin was not given to the control group, no blood sample was taken from these patients for mutation screening. The reason why there are 36 patients in the study group in this table is to indicate that there are 6 patients who were included in the study group but were removed from the study group because of a mutation and were replaced by additional patients.",Participants,,Count of Participants
NCT04646109,6045658,Primary,Changes in Serum D-dimer Levels,"Baseline serum D-dimer levels (mg/L) of the patients were recorded in both groups. Then, their treatments were started and serum D-dimer levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum D-dimer levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum D-dimer level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,mg/L,Standard Deviation,Mean
NCT04646109,6045659,Primary,Changes in Serum Ferritin Levels,"Baseline serum ferritin levels (mg/dL) of the patients were recorded in both groups. Then, their treatments were started and serum ferritin levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum ferritin levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum ferritin level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,mg/dL,Standard Deviation,Mean
NCT04646109,6045660,Primary,Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L),"Baseline PNL/L ratio of the patients were recorded in both groups. Then, their treatments were started and PNL/L ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PNL/L ratios on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the PNL/L ratio at the end of the 5th day (primary endpoint) with the baseline ratio was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,Ratio,Standard Deviation,Mean
NCT04646109,6045661,Primary,Changes in Serum Lymphocyte Counts,"Baseline Serum Lymphocyte counts (cell/mm^3) of the patients were recorded in both groups. Then, their treatments were started and Serum Lymphocyte counts at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in Serum Lymphocyte counts on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the Serum Lymphocyte count at the end of the 5th day (primary endpoint) with the baseline count was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,cell/mm^3,Standard Deviation,Mean
NCT04646109,6045662,Primary,Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2),"Baseline PaO2/FiO2 ratios of the patients were recorded in both groups. Then, their treatments were started and PaO2/FiO2 ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PaO2/FiO2 ratios on the 1st, 3rd and 5th days after the basal ratio was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,Ratio,Standard Deviation,Mean
NCT04646109,6045663,Primary,Changes in Oxygen Saturation (SpO2) Values,"Baseline SpO2 values of the patients were recorded in both groups. Then, their treatments were started and SpO2 values at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in SpO2 values on the 1st, 3rd and 5th days after the basal value calculated graphically, the change in the SpO2 value at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value).",From starting to the end of ivermectin therapy (0 to the end of 5th day),,percentage of peripheral capillary O2,Standard Deviation,Mean
NCT04646109,6045664,Primary,Number of Participants With Clinical Response,"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as clinical response: Extubation in mechanically ventilated patients, respiratory rate <26/min, SpO2 level in room air >90%, PaO2/FiO2 >300 in patients receiving oxygen, presence of at least two of the 2-point reduction criteria in Sequential Organ Failure Assessment (SOFA) score.",From starting to the end of ivermectin therapy (0 to the end of 5th day),,Participants,,Count of Participants
NCT04646109,6045665,Primary,Systolic and Diastolic Pressure Means of the Patients,"At the beginning of the study, the systolic and diastolic pressures (as mmHg) of the patients were measured and the mean systolic and diastolic pressure values of both groups were recorded.",At the first day of the study,,mmHg,Standard Deviation,Mean
NCT04646109,6045666,Primary,Respiratory Rate Means of the Patients,"At the beginning of the study, the respiratory rates (as per minute) of the patients were measured and the mean respiratory rate values of both groups were recorded.",At the first day of the study,,breaths per minute,Standard Deviation,Mean
NCT04435808,6045852,Secondary,Adverse Effect Profile of Hydroxychloroquine,Will assess the adverse effect profile of the study drug via serial surveys,3 months,,,,
NCT04646109,6045668,Primary,Body Temperature Means of the Patients,"At the beginning of the study, the body temperatures (as degree celcius) of the patients were measured and the mean body temperature values of both groups were recorded.",At the first day of the study,,Degree celcius,Standard Deviation,Mean
NCT04646109,6045669,Primary,Percentage of Patients With Baseline Clinical Symptoms,"At the beginning of the study, the patients were asked whether there were any of the following clinical symptoms and the percentage of patients with any of the clinical symptoms in both groups were recorded:~Fever~Cough~Sore throat~Dispnea~Headache~Weakness~Myalgia~Diarrhea~Nausea or vomiting",At the first day of the study,,Participants,,Count of Participants
NCT04646109,6045670,Primary,Percentage of Patients With Accompanying Diseases,"At the beginning of the study, the patients were asked whether there were any of the following accompanying diseases and the percentage of patients with accompanying disease in both groups were recorded:~Diabetes mellitus~Hypertension~Coronary artery disease~Cardiac failure~Chronic obstructive pulmonary disease~Malignancy~Immunodeficiency",At the first day of the study,,Participants,,Count of Participants
NCT04646109,6045671,Primary,Age Distribution of the Patients,The age of the patients (years) in both groups were recorded at the time of inclusion.,At the first day of the study,,Years,Standard Deviation,Mean
NCT04646109,6045672,Primary,Gender Distribution of the Patients,The gender of patients (Male/female) in both groups were recorded at the time of inclusion.,At the first day of the study,,Participants,,Count of Participants
NCT04542694,6045708,Secondary,Time Before the End of Fever,Time (in days) before the end of fever (body temperature < 37.2 ° C for 3 consecutive days without antipyretic medication).,28 days,patients who received at least one dose of the drug in the study and for whom there is data for at least one visit after the baseline,days,Inter-Quartile Range,Median
NCT04542694,6045709,Secondary,Rate of Viral Elimination by Day 10,Percentage of patients with elimination (clearance) of COVID-19 according to PCR data by day 10 (negative PCR results).,10 days,patients who received at least one dose of the drug in the study and for whom there is data for at least one visit after the baseline,Participants,,Count of Participants
NCT04542694,6045700,Post-Hoc,A Number of Patients With Fever Reduction Below 37.2 ° C by the 3rd Day of Therapy,,3 days,,Participants,,Count of Participants
NCT04542694,6045701,Post-Hoc,The Number of Patients Achieved a Category Lower Than or Equal to 2 on the WHO Clinical Improvement Scale (They Were Discharged From Hospital),,10 days,,Participants,,Count of Participants
NCT04542694,6045702,Post-Hoc,Amount of Patients Without Any Clinical Signs of Disease by the Completion of Therapy (Category 0 According to a WHO Categorical Ordinal Scale),,10 days,,Participants,,Count of Participants
NCT04542694,6045703,Secondary,Mortality,Incidence of fatal cases (% of patients),28 Days,the number of patients who died,Participants,,Count of Participants
NCT04542694,6045704,Secondary,Rate of the Use of Mechanical Ventilation,Percentage of cases with mechanical lung ventilation (% of patients),28 Days,the number of patients who required mechanical lung ventilation,Participants,,Count of Participants
NCT04542694,6045705,Secondary,Rate of the Use of Non-invasive Lung Ventilation,Percentage of cases with non-invasive lung ventilation (% of patients).,28 Days,the number of patients who required non-invasive lung ventilation,Participants,,Count of Participants
NCT04542694,6045706,Secondary,Rate of Transfer to the Intensive Care Unit,Percentage of patients transferred to intensive care unit (% of patients).,28 Days,the number of patients who required transfer to the intensive care unit,Participants,,Count of Participants
NCT04542694,6045707,Secondary,Change in the Level of Lung Damage According to CT,Assessment of lung injury (degree of damage by empirical visual scale and % of patients) according to CT data comparing to baseline. The number of patients in whom by the end of therapy there was an improvement in the condition of the lungs (a decrease in the volume of the lesion according to CT),"Days 15, 21, 28",The number of patients in whom by the end of therapy there was an improvement in the condition of the lungs (a decrease in the volume of the lesion according to CT),Participants,,Count of Participants
NCT04542694,6045710,Primary,Time to Clinical Improvement,Time (in days) to improvement in clinical status by WHO categorical ordinal scale of clinical status improvement.,28 days,patients who received at least one dose of the drug in the study and for whom there is data for at least one visit after the baseline,days,Inter-Quartile Range,Median
NCT04542694,6045711,Primary,Rate of Clinical Status Improvement,"Rate of clinical status improvement by categorical ordinal scale of clinical status improvement by 2 or more categories by Day 10 WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), 0 - uninfected (There are no clinical and virological signs of infection), 8 - dead, higher scores mean a worse outcome","By Visit 3, approximately 10 days",Intent-tо-treat population,Participants,,Count of Participants
NCT04542226,6045712,Secondary,Number of Participants With Discontinuation of Drug Administration,Number of participants with Permanent or temporary discontinuation of infusions or injections due to adverse events,Days 1 - 17.,,Participants,,Count of Participants
NCT04542226,6045713,Secondary,The Number of Participants With Adverse Events,The number of participants with adverse events (AE),Days 1 - 29.,,Participants,,Count of Participants
NCT04542226,6045714,Secondary,The Number of Participants With Serious Adverse Events,The number of participants with serious adverse events (SAE),Days 1 - 29.,,Participants,,Count of Participants
NCT04542226,6045715,Secondary,Mortality,Number of participants who were dead or alive (Days 1 - 29),Days 1 - 29.,,Participants,,Count of Participants
NCT04542226,6045716,Secondary,Hospitalisation Duration,Duration of hospitalisation,Days 1 - 29,Administration of Polyoxidonium was canceled due to Adverse event in 1 patient. Patient received only 2 injections.This is the reason why the needed information for this Outcome Measure is absent for 1 patient.,days,Standard Deviation,Mean
NCT04542226,6045717,Secondary,Number of Patients Requiring Supplementary Oxygen,"Number of patients requiring supplementary oxygen on Days 3, 5, 8, 11, 15, 29","Days intervals 1 (baseline), 3, 5, 8, 11, 15, 29.",,Participants,,Count of Participants
NCT04542226,6045718,Secondary,Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale)),"NEWS scale score status, time to a discharge from a hospital or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.~NEWS score is based on 7 clinical parameters:~respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, temperature. A score of 0, 1, 2, 3 is allocated to each parameter except supplemental oxygen (a score 0 or 1 is allocated) and level of consciousness (a score 0 or 3 is allocated). A higher score means the parameter is further from the normal range. All scores were summed to get an aggregate score. Aggregate score ranges from 0 to 19, with higher scores meaning higher risk.~Low risk - aggregate score, 1-4 Low to medium risk - score 3 in any single parameter, Medium risk - aggregate score 5-6, High risk - aggregate score 7-19.",Days 1 - 29.,Administration of Polyoxidonium was canceled due to Adverse event in 1 patient. Patient received only 2 injections.This is the reason why the needed information for this Outcome Measure is absent for 1 patient.,days,Standard Deviation,Mean
NCT04542226,6045719,Secondary,Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score,"Ordinal scale (OS) score status, time to improvement by 1 point for each OS score.~Subject clinical status using the 7-point Ordinal Scale:~- Not hospitalized, no limitations on activities;~- Not hospitalized, limitation on activities;~- Hospitalized, not requiring supplemental oxygen;~- Hospitalized, requiring supplemental oxygen;~- Hospitalized, on non-invasive ventilation or high flow oxygen devices;~- Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation;~- Death.",Days 1 - 29.,Administration of Polyoxidonium was canceled due to Adverse event in 1 patient. Patient received only 2 injections.This is the reason why the needed information for this Outcome Measure is absent for 1 patient.,days,Standard Deviation,Mean
NCT04542226,6045720,Primary,Clinical Status of the Patient (According to 7-point Ordinal Scale),"Subject clinical status using the 7-point Ordinal Scale, specified as the primary endpoint in the WHO Master Protocol on day 15 as compared to baseline~(1 - Not hospitalized, no limitations on activities; 2 - Not hospitalized, limitation on activities; 3 - Hospitalized, not requiring supplemental oxygen; 4 - Hospitalized, requiring supplemental oxygen; 5 - Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6 - Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 7 - Death).","Day 1 (Baseline), Day 15",,Participants,,Count of Participants
NCT04491240,6045778,Secondary,Lactic Acid Dehydrogenase (LDH),Lactic Acid Dehydrogenase (LDH) level in serum,At the beginning of inhalation (day 1) and on next day of last inhalation (day 11),,U/L,Full Range,Mean
NCT04491240,6045779,Secondary,C-reactive Protein,Blood biochemistry C reactive protein level in serum.,At the begining of inhalation (day 1) and on next day of last inhalation (day 11),,mg/L,Full Range,Mean
NCT04523831,6045757,Secondary,Number of Patients Remain Persistently Positive for RT-PCR of Covid-19,Number of Patients remain positive for RT-PCR of Covid-19 at day 14 after the day of initial positivity.,14 days,Intention to treat analysis. Binary logistic regression,Participants,,Count of Participants
NCT04523831,6045758,Secondary,Number of Patients Having Clinical Deterioration.,"Number of patients deteriorating to next level of severity, like moderate, severe and death. That is from mild illness at presentation with subsequent follow up developed moderate, severe illness or death. Like wise from moderate illness at presentation developed severe illness or death.~Mild illness: These patients usually present with symptoms of an upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, or malaise. Signs and symptoms of a more serious disease, such as dyspnea, are not present Moderate illness: Respiratory symptoms such as cough and shortness of breath (or tachypnea in children) are present without signs of severe pneumonia.~Severe illness:severe dyspnea, respiratory distress, tachypnea (> 30 breaths/min), and hypoxia (SpO2 < 90% on room air).",1 month,Intention to treat analysis. Binary Logistic regression,Participants,,Count of Participants
NCT04523831,6045759,Primary,Number of Participants With Late Clinical Recovery,Number of the patients required more than 12 days for clinical improvement as defined above.,12 days,Intention to treat analysis. Binary logistic regression,Participants,,Count of Participants
NCT04523831,6045760,Primary,Number of Patients With Early Clinical Improvement,"Number of patients have clinical improvement as described by WHO and Bangladesh local guideline with 7 days..~Body temperature remains normal for at least 3 days (ear temperature is lower than 37.5 °C).~Respiratory symptoms are significantly improved.~Lung imaging shows obvious improvement in lesions.~There is no co-morbidities or complications which require hospitalization.~SpO2, >93% without assisted oxygen inhalation.",7 days,Intention to treat analysis. Linear logistic regression,Participants,,Count of Participants
NCT04491994,6045776,Secondary,Viral Clearance,PCR negativity on day 7 and 14 after admission,14 days,,,,
NCT04491994,6045777,Primary,Number of Participants With Progression,"After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status",5 days,,Participants,,Count of Participants
NCT04400682,6045890,Primary,AUC0-tlast,AUC0-tlast of favipiravir will be obtained from plasma concentrations,0 to 24 hours post dose,,ng*hr/mL,Standard Deviation,Least Squares Mean
NCT04491240,6045780,Secondary,SpO2 Concentration,The concentration of SpO2 by Pulse oximetry device during procedures in the groups. The measure was done before and after each inhalation (total 4 measures per day). The intraday SpO2 data of all patients in groups was calculated as Median with Inter-Quartile Range and presented in the table by days.,10 days during inhalation,,O2 concentration in percent,Inter-Quartile Range,Median
NCT04491240,6045781,Secondary,Time to Clinical Recovery (TTCR),Measure and compare time to clinical recovery compared to placebo. Time to clinical recovery calculated by the number of days the patient has hospitalized.,"from first inhalation until discharge from the clinic, up to 30 days",,days,Standard Deviation,Mean
NCT04491240,6045782,Primary,Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure,Safety assessments such as adverse events during the inhalation procedures will be registered.,after each inhalation during 10 days,,Participants,,Count of Participants
NCT04491240,6045783,Primary,Number of Participants With Non-serious and Serious Adverse Events During Trial,Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial,30 days after clinic discharge,,Participants,,Count of Participants
NCT04435808,6045853,Secondary,Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection,Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include determination of the need for ICU care.,3 months,,,,
NCT04435808,6045850,Secondary,Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates,"Will perform mNGS on any recovered SARS-CoV-2 isolates from subjects to identify the genomic lineage of the virus and to compare this with SARS-CoV-2 genomes circulating in the hospital system, the community and nationally. This may provide evidence as to the source of the infection (e.g. a hospital-based infection vs. a community infection vs. a travel-associated infection out of state).",3 months,,,,
NCT04435808,6045851,Secondary,Seroconversion Following SARS-CoV-2 Infection,Will collect monthly blood samples for serological analysis,3 months,,,,
NCT04435808,6045854,Secondary,Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection,Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include assessments of hospital admissions.,3 months,,,,
NCT04435808,6045855,Secondary,Occupational Health Exposure,Assess the role of exposure levels to Covid-19 patients amongst health care workers and its impact of infection rates,3 months,,,,
NCT04435808,6045856,Secondary,Symptomatic vs. Asymptomatic Infection With SARS-CoV-2,Determine the frequency of symptomatic vs. asymptomatic SARS-CoV-2 infections in health care workers during the study via serial PCR testing and symptom surveys,3 months,,,,
NCT04435808,6045857,Primary,SARS-CoV-2 Infection,Number of health care workers who become infected with SARS-CoV-2 as detected by PCR,3 months,DSMB stopped trial early prior to any data collection.,,,
NCT04425863,6045858,Primary,Adverse Events,Patient presenting serious adverse events,14 days,,Participants,,Count of Participants
NCT04425863,6045859,Primary,Patients Needing Drug Dose Adjustment,Patients who needed dose adjustment of any of the drugs involved in the treatment protocol,14 days,,Participants,,Count of Participants
NCT04425863,6045860,Primary,Mortality,Patients who died within 30 days after enrollment,30 days,,Participants,,Count of Participants
NCT04425863,6045861,Primary,ICU-treated Patients After 2-week Treatment,Number of patients needing ICU-treatment including mechanical ventilation after 2-week treatment,14 days,,Participants,,Count of Participants
NCT04425863,6045862,Primary,Patients Who Improved Their Condition or Did Not Worsen it,"Number of patients who did not go to a more severe stage of disease or die (i.e. they neither go from mild to moderate or severe, nor go from moderate to severe or die, if they had been already enrolled in a severe condition)",7 days,,Participants,,Count of Participants
NCT04425850,6045863,Secondary,Adverse Events Other Than Those Resulting From Contagion or Disease Progression,Adverse events reported by subjects of each arm are recorded other than those resulting from contagion or disease progression,28 days,Hispanic,Participants,,Count of Participants
NCT04425850,6045864,Primary,Number of Infected Subjects,Number of participants testing positive for COVID-19 after inclusion in each arm,28 days,Hispanic,Participants,,Count of Participants
NCT04422561,6045865,Secondary,Development of COVID,by swab,within 14 days after enrollement,,,,
NCT04422561,6045866,Primary,"Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)",history taking and clinical examination,within 14 days after enrollement,,Participants,,Count of Participants
NCT04410159,6045867,Secondary,Number of Patients With Abnormal Laboratory Findings,Abnormal absolute lymphocytic count Abnormal C-reactive protein,Day 0-14,,Participants,,Count of Participants
NCT04410159,6045868,Secondary,Number of Patients With Abnormal Radiological Findings,abnormal chest x-ray or CT scan,Day 0-14,,Participants,,Count of Participants
NCT04410159,6045869,Secondary,Number of Patients That Progress to More Severe Disease,Presence of signs and symptoms of more severe COVID19 Based symptoms diary and clinical evaluation,Day 12,,Participants,,Count of Participants
NCT04410159,6045870,Secondary,Number of Participants With Negative RT-PCR Results,RT-PCR (swabs from oropharynx and nasopharynx) taken at day 12,Day 12,,Participants,,Count of Participants
NCT04410159,6045871,Primary,Number of Participants With Early Viral Clearance,Viral clearance is defined as two negative RT-PCR (of swabs from oropharynx and nasopharynx) results at least 24 hours apart,Day 6,,Participants,,Count of Participants
NCT04406194,6045872,Secondary,Tmax of Favipiravir,Time to reach maximum plasma concentration of favipiravir,0 to 24 hours post-dose,29 subjects were analysed and included in statistical analysis.,hr,Standard Deviation,Mean
NCT04406194,6045873,Secondary,AUC0-inf of Favipiravir,Area under the plasma concentration curve to infinite time of favipiravir,0 to 24 hours post-dose,29 subjects were analysed and included in statistical analysis.,ng*hr/mL,Standard Deviation,Mean
NCT04406194,6045874,Primary,Cmax of Favipiravir,Maximum plasma concentration of favipiravir,0 to 24 hours post-dose,29 subjects were analysed and included in statistical analysis.,ng/mL,Standard Deviation,Mean
NCT04406194,6045875,Primary,AUC0-tlast of Favipiravir,Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hours,0 to 24 hours post-dose,29 subjects were analysed and included in statistical analysis.,ng*hr/mL,Standard Deviation,Mean
NCT04400682,6045888,Secondary,AUC0-inf of Favipiravir,AUC0-inf of favipiravir will be obtained from plasma concentrations,0 to 24 hours post dose,All of the 25 subjects were included in statistical analysis,ng*hr/mL,Standard Deviation,Least Squares Mean
NCT04400682,6045889,Primary,Favipiravir Cmax,Favipiravir Cmax Cmax of favipiravir will be obtained from plasma concentrations,0 to 24 hours post dose,All of the 25 subjects were included in statistical analysis.,ng/mL,Standard Deviation,Least Squares Mean
NCT04400682,6045887,Secondary,Tmax of Favipiravir,tmax of favipiravir will be obtained from plasma concentrations,0 to 24 hours post dose,All of the 25 subjects were included in statistical analysis.,hr,Standard Deviation,Mean
NCT04390022,6045918,Secondary,Results From Cytokine Human Magnetic 30-Plex Panel,"Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher).~[Results not yet available]",Up to and including day 28,,,,
NCT04390022,6045919,Secondary,Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells,"Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry.~[Results not yet available]",Up to and including day 7,,,,
NCT04390022,6045920,Secondary,Frequency of Innate Immune Cells,"Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry.~[Results not yet available]",Up to and including day 7,,,,
NCT04390022,6045921,Secondary,"Levels of IgG, IgM and IgA","Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay.~[Results not yet available]",Up to and including day 28,,,,
NCT04390022,6045922,Secondary,Proportion of Drug-related Adverse Events,Proportion of drug-related adverse events,7 days post treatment,,Participants,,Count of Participants
NCT04390022,6045923,Secondary,Seroconversion at Day 21,Proportion of participants with positive IgG at day 21,Up to and including day 21,,Participants,,Count of Participants
NCT04390022,6045924,Secondary,Fever and Cough Progression,Proportion of patients with fever and cough,"Days 4, 7, 14 and 21",,Participants,,Count of Participants
NCT04390022,6045925,Secondary,Median Viral Load,Quantitative and semi-quantitative PCR in nasopharyngeal swab. PCRs were performed using two target genes (E and N).,"Baseline and on days 4, 7, 14 and 21",,copies/mL,Inter-Quartile Range,Median
NCT04390022,6045926,Primary,Proportion of Patients With a Positive SARS-CoV-2 PCR,Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. PCRs were performed using two target genes (E and N).,7 days post-treatment,,Participants,,Count of Participants
NCT04385238,6045927,Primary,Number of Participants With Symptoms of Anxiety and Depression,Symptoms of anxiety and depression will be measured by the Patient Health Questionnaire-4 (PHQ-4) which combines two ultrabrief screeners: the PHQ-2 and the Generalised Anxiety Disorder Scale. Participants will be asked to report their symptoms of depression and anxiety in the past 2 weeks on a Likert Scale from 0 (not at all) to 3 (nearly every day) for a maximum score of 12.,Anytime during pregnancy or within 6 months after given birth.,,Participants,,Count of Participants
NCT04385238,6045928,Primary,Number of Participants With Symptoms of Post-traumatic Stress Disorder,"Post-traumatic Stress Disorder (PTSD) Symptoms will be assessed by the Impact of Events Scale-6. This scale includes a total of six items: two items from each of the three subscales of the measure, namely intrusion, hyperarousal and avoidance. Participants will be asked to report their PTSD symptoms in the past 7 days on a Likert Scale ranging from 0 (not at all) to 4 (extremely).",Anytime during pregnancy or within 6 months after given birth.,,Participants,,Count of Participants
NCT04343261,6046028,Primary,Serum Antibody Titers,"Median Serum Antibody Titers at Day 0, Day 3, Day 5 and Day 7 Serum Antibody titers were measured using chemiluminescent SARS-CoV-2 immunoglobulin G (IgG) assay from Diazyme (Poway, CA) Positive IgG serum value is > or = 1.0 arbitrary units/mL [AU/mL] (linear reportable range for IgG is 0.20 - 100.00 AU/mL)","Day 0, Day 3, Day 5, and Day 7","39 out of 41 patients had blood collected on day 0 (pre-transfusion), and on post-transfusion day 3 (n=36), 5 (n=30), and 7 (n=24) and serum antibody titers was assessed at each time point.",arbitrary units/mL (AU/mL),Full Range,Median
NCT04343261,6046029,Primary,Viral Load,"Median Viral Load at Day 0, Day 3, Day 5, and Day 7 Plasma Viral Load was measured using a research-use only real-time reverse transcription polymerase chain reaction (rRT -PCR) method which targets two regions of the SARS-CoV-2 N gene using TaqMan chemistry.~The limit of detection for this assay is 75 copies/mL (standard curve of 75 copies/mL to 10,000,000 copies/mL of in vitro transcribed RNA prepared from the full SARS-CoV-2 N gene).","Day 0, Day 3, Day 5, and Day 7",Plasma viral load data was available for 35 out of 41 convalescent plasma recipients on day 0. 22 patients out of 35 had non-detectable levels at Day 0; 25 patients out of 34 had non-detectable levels on Day 3; 20 patients out of 27 had non-detectable levels on Day 5; 20 patients out of 24 had non-detectable levels on Day 7.,copies per mL,Full Range,Median
NCT04343261,6046030,Primary,Mortality,Mortality within 28 days,Up to 28 days,48 patients with severe or life threatening disease with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection enrolled in the study. 7 patients were excluded from analysis due to receiving plasma with insufficient antibodies.,Participants,,Count of Participants
NCT04343092,6046037,Secondary,Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group,"Time to cure is evaluated by measuring time from admission of the patient to the hospital till discharge after being free of symptoms and negative PCR swab. Once nasopharyngeal and oropharyngeal swab viral PCR testing yielded negative results 2 times consecutively, no further testing was performed",4 week,,Days,Standard Deviation,Mean
NCT04343092,6046038,Primary,Number of Cured Patients,Primary outcome is assessed by calculating the number of patients who had symptoms free and two successive readings of negative PCR swab.,4 weeks,,Participants,,Count of Participants
NCT04329923,6046043,Secondary,Rate of Hospitalization,Cohort 1 rate of hospitalization,until quarantine release,,Participants,,Count of Participants
NCT04329923,6046044,Secondary,Rate of Housemate Infection,Cohort 1 rate of participant-reported secondary infection of housemates,"until quarantine release, or approximately <20 days",,Participants,,Count of Participants
NCT04329923,6046045,Primary,Number of Health Care Workers Who Developed SARS-COV-2 Infection,Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months,2 months,,Participants,,Count of Participants
NCT04329923,6046046,Primary,Time to Hospital Discharge,Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital discharge,until hospital discharge,,days,Full Range,Median
NCT04329923,6046047,Primary,Time to Release From Quarantine Time,Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset.,until quarantine release or hospitalization,randomized patients that were released from quarantine on study,days,Full Range,Median
NCT04323592,6046073,Secondary,Number of Days Free From Mechanical Ventilation,number of days free from mechanical ventilation (both invasive and non-invasive) by day 28,28 days,,days,Standard Deviation,Mean
NCT04323592,6046074,Secondary,Change in C-reactive Protein (CRP),Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.,7 days,,mg/L,Standard Deviation,Mean
NCT04323592,6046075,Primary,Endotracheal Intubation (Invasive Mechanical Ventilation),We reported below the number of participants who needed endotracheal intubation during ICU admission,28 days,,Participants,,Count of Participants
NCT04323592,6046076,Primary,Admission to Intensive Care Unit (ICU),We reported below the number of participants admitted to ICU within 28 days.,28 days,,Participants,,Count of Participants
NCT04323592,6046077,Primary,In-hospital Death Within 28 Days,"We reported below the number of participants who died within 28 days, during the hospital stay.",28 days,,Participants,,Count of Participants
NCT04323592,6046078,Primary,"Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28",We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.,28 days,,Participants,,Count of Participants
NCT04292899,6046237,Secondary,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study treatment start date and no later than 30 days after the permanent discontinuation of the study treatment and/or the AEs that led to premature discontinuation of study treatment.,First dose date up to last dose date (maximum: 10 days) plus 30 days,Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study drug,percentage of participants,95% Confidence Interval,Number
NCT04292899,6046238,Primary,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14,"Clinical status was derived from death, hospital discharge, and the ordinal scale as follows: score of 1 was used for all days on or after the date of death; score of 7 was used for all days on or after discharged alive date; last assessment carried forward for any missing values.The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or ECMO; 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration); 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for the Remdesivir for 10 days group vs the Remdesivir for 5 days group.",Day 14,Full Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.,percentage of participants,,Number
NCT04292730,6046239,Secondary,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),"TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.",First dose date up to last dose date (maximum: 10 days) plus 30 days,Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).,percentage of participants,95% Confidence Interval,Number
NCT04292730,6046240,Primary,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11,"Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of 1 was used for all days on or after the date of death; score of 7 was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.",Day 11,Full Analysis Set (FAS) included all participants who were randomized into Part A of the study and received at least 1 dose of study treatment if randomized to 1 of the RDV treatment groups. Participants in the SOC arm who had protocol Day 1 visit were included in the FAS.,percentage of participants,,Number
NCT04280705,6046416,Secondary,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First","The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. The time to discharge or a NEWS of less than or equal to 2 was determined for each participant.",Day 1 through Day 29,The ITT population includes all participants as randomized.,Days,95% Confidence Interval,Median
NCT04280705,6046417,Secondary,Time to an Improvement of at Least Two Categories Using an Ordinal Scale,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Time to improvement by at least two categories was determined for each participant",Day 1 through Day 29,The ITT population includes all participants as randomized,Days,95% Confidence Interval,Median
NCT04280705,6046418,Secondary,Time to an Improvement by at Least One Category Using an Ordinal Scale,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Time to improvement by at least one category was determined for each participant",Day 1 through Day 29,The ITT population includes all participants as randomized,Days,95% Confidence Interval,Median
NCT04280705,6046419,Secondary,29-day Participant Mortality,The mortality rate was determined as the proportion of participants who died by study Day 29.,Day 1 through Day 29,The ITT population includes all participants as randomized,Proportion of participants,95% Confidence Interval,Number
NCT04280705,6046420,Secondary,14-day Participant Mortality,The mortality rate was determined as the proportion of participants who died by study Day 15.,Day 1 through Day 15,The ITT population consists of all participants as randomized.,Proportion of participants,95% Confidence Interval,Number
NCT04280705,6046441,Secondary,Change From Baseline in Eosinophils,"Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046421,Secondary,Mean Change in the Ordinal Scale,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement.","Day 1, 3, 5, 8, 11, 15, 22, and 29",The intent-to-treat (ITT) population includes all participants who were randomized reporting a clinical score. Missing values were imputed using Last Observation Carried Forward. Clinical scores of 8 were carried forward from the date of death for participants who died.,units on a scale,Standard Deviation,Mean
NCT04280705,6046422,Secondary,Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,The percentage of participants requiring new ventilator or ECMO use was determined as the percentage not on a ventilator or ECMO at baseline,Day 1 through Day 29,The analysis population is restricted to randomized participants not on a ventilator or ECMO at baseline.,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046423,Secondary,Percentage of Participants Requiring New Oxygen Use,The percentage of participants requiring new oxygen use was determined as the percentage of participants not requiring oxygen at baseline,Day 1 through Day 29,The analysis population is restricted to randomized participants not requiring oxygen at baseline.,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046424,Secondary,Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use,New non-invasive ventilation or high-flow oxygen use was determined as the percentage of subject not on non-invasive ventilation or high-flow oxygen at baseline.,Day 1 through Day 29,The analysis population is restricted to randomized participants who were not on non-invasive or high-flow oxygen at baseline.,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046425,Secondary,Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,"Duration of new ventilator or ECMO use was measured in days among participants who were not on a ventilator or ECMO at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die",Day 1 through Day 29,The analysis population is restricted to randomized participants not on a ventilator or ECMO at baseline but who subsequently required a ventilator or ECMO.,Days,Inter-Quartile Range,Median
NCT04280705,6046426,Secondary,Duration of New Oxygen Use,"Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die~.",Day 1 through Day 29,The analysis population is restricted to randomized participants who were not on oxygen at baseline but who subsequently required oxygen.,Days,Inter-Quartile Range,Median
NCT04280705,6046427,Secondary,Duration of New Non-invasive Ventilation or High Flow Oxygen Use,"Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die",Day 1 through Day 29,The analysis population is restricted to randomized participants who were not on non-invasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.,Days,Inter-Quartile Range,Median
NCT04280705,6046428,Secondary,Duration of Hospitalization,Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.,Day 1 through Day 29,The intent-to-treat (ITT) population includes all participants who were randomized,Days,Inter-Quartile Range,Median
NCT04280705,6046429,Secondary,Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics,"Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses.",Day 1 through Day 10,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046430,Secondary,Percentage of Participants Reporting Serious Adverse Events (SAEs),"An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.",Day 1 through Day 29,"The safety population includes all participants with available data post baseline, analyzed as treated.",percentage of participants,95% Confidence Interval,Number
NCT04280705,6046431,Secondary,Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs),"Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.",Day 1 through Day 29,"The safety population includes all participants with available data post baseline, analyzed as treated.",percentage of participants,95% Confidence Interval,Number
NCT04280705,6046432,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 29,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046433,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 22,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046434,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 15,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046435,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 11,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046436,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 8,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046437,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 5,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046438,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 3,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046439,Secondary,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1,"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.",Day 1,The intent-to-treat (ITT) population includes all participants who were randomized,percentage of participants,95% Confidence Interval,Number
NCT04280705,6046440,Secondary,Change in National Early Warning Score (NEWS) From Baseline,"The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome.","Days 1, 3, 5, 8, 11, 15, 22, and 29",The intent-to-treat (ITT) population includes all participants who were randomized with data at baseline and at each timepoint.,units on a scale,Standard Deviation,Mean
NCT04280705,6046442,Secondary,Change From Baseline in Basophils,"Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046443,Secondary,Change From Baseline in Monocytes,"Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046444,Secondary,Change From Baseline in Lymphocytes,"Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046445,Secondary,Change From Baseline in Neutrophils,"Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046446,Secondary,Change From Baseline in White Blood Cell Count (WBC),"Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046447,Secondary,Change From Baseline in Total Bilirubin,"Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",mg/dL,Standard Deviation,Mean
NCT04280705,6046448,Secondary,Change From Baseline in Prothrombin Time (PT),"Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",seconds,Standard Deviation,Mean
NCT04280705,6046449,Secondary,Change From Baseline in Platelets,"Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",10^9 cells/liter,Standard Deviation,Mean
NCT04280705,6046450,Secondary,Change From Baseline in Hemoglobin,"Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",grams/deciliter (g/dL),Standard Deviation,Mean
NCT04280705,6046451,Secondary,Change From Baseline in Glucose,"Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",mg/dL,Standard Deviation,Mean
NCT04280705,6046452,Secondary,Change From Baseline in Creatinine,"Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",milligrams/deciliter (mg/dL),Standard Deviation,Mean
NCT04280705,6046453,Secondary,Change From Baseline in Aspartate Transaminase (AST),"Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",Units/Liter (U/L),Standard Deviation,Mean
NCT04280705,6046454,Secondary,Change From Baseline in Alanine Transaminase (ALT),"Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","Days 1, 3, 5, 8, 11, 15 and 29","The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.",Units/Liter (U/L),Standard Deviation,Mean
NCT04280705,6046455,Primary,Time to Recovery,"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.",Day 1 through Day 29,The intent-to-treat (ITT) population includes all participants who were randomized,Days,95% Confidence Interval,Median
NCT04674644,6417156,Secondary,The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale,"Coronavirus Anxiety Scale is an unidimensional tool that assesses the physiological anxiety related to the COVID-19. Participants rated 5 items on a 5-point Likert-type scale, from 0 (not at all) to 4 (nearly every day over the last 2 weeks). Scores are added up for a total score of 0 - 20, with higher scores indicating worse outcomes.",during the survey administration,,scores on a scale,Standard Deviation,Mean
NCT04674644,6417157,Primary,The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale,Fear of COVID-19 Scale is an unidimensional scale seven-item scale assessing anxiety regarding COVID-19 . Items are rated on a 5-item Likert scale from 1 (Strongly disagree) to 5 (Strongly agree) with scores ranging from 7 to 35. Scores are added up. A higher score of the FCV-19S represents a greater level of fear and a worse outcome.,during the survey administration,,scores on a scale,Standard Deviation,Mean
NCT04446429,6419552,Primary,COVID-19 Hospitalization,Percentage of subjects hospitalized due to COVID-19,30 days,,percentage of subjects,,Number
NCT04331366,6441875,Secondary,Count of Participants With Subjective Work of Breathing,"Participants were observed for stridor, grunting, nasal flaring, or accessory muscle use. The presence of any of these indicates that increased effort is required for breathing.","Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)",Data on subjective work of breathing were not collected at the Baseline and Minute 30 time points.,Participants,,Count of Participants
NCT04331366,6441876,Secondary,Blood Pressure,"Systolic and diastolic blood pressure was assessed before treatment, during treatment, and 15 minutes after the end of treatment.","Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)",,mmHg,Standard Deviation,Mean
NCT04331366,6441877,Secondary,Heart Rate,"Heart rate, in beats per minute, was assessed before treatment, during treatment, and 15 minutes after the end of treatment.","Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)",,beats per minute,Standard Deviation,Mean
NCT04331366,6441878,Secondary,Respiratory Rate,"The number of breaths per minute was assessed before treatment, during treatment, and 15 minutes after the end of treatment.","Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)",,breaths per minute,Standard Deviation,Mean
NCT04331366,6441879,Primary,Oxygen Saturation by Pulse Oximetry,Pulse oximetry is a way to assess whether or not a patient needs help breathing. Oxygen saturation levels for healthy individuals are 95% and above.,"Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)",,percentage of oxygen saturation,Standard Deviation,Mean
